We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Too Few Medicines for Children With Cancer—Reply

Peter C. Adamson, MD1
[+] Author Affiliations
1Children’s Oncology Group, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
JAMA Pediatr. 2014;168(6):583-584. doi:10.1001/jamapediatrics.2014.18.
Text Size: A A A
Published online


In Reply I thank Herold et al for their thoughtful letter and their commitment to improving the drug development process for children with cancer. As a leader of an international collaborative childhood cancer research organization, in my experience—contrary to their conclusion—the process surrounding pediatric investigation plan approvals is delaying the onset of a number of pediatric phase 1 cancer trials. While it is fully appreciated that completed early-phase trials have been accepted in the past by the European Medicines Agency, it is likely the effect of regulatory uncertainty1 that leads a number of biopharmaceutical industry sponsors to delay the onset of pediatric clinical research until a pediatric investigation plan is approved.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2014
Ralf Herold, MD, PhD; Agnès Saint-Raymond, MD; Koenraad Norga, MD, PhD
1European Medicines Agency, London, United Kingdom
2Department of Paediatric Oncology, Antwerp University Hospital (UZA), Edegem, Belgium3Department of Medicine and Health Sciences, Antwerp University, Wilrijk, Belgium
JAMA Pediatr. 2014;168(6):583. doi:10.1001/jamapediatrics.2014.15.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...